Helping Imaging Systems See Diseases They Couldn’t See Before
Researchers are developing a new class of imaging agents that will allow MRI, CT, and X-ray machines to see diseases such as multiple sclerosis, Alzheimer’s, and cardiac disease.
Researchers in GE’s Nanotechnology Lab have developed promising nanoparticle-based imaging agents that could increase imaging resolution and sensitivity. The ability to see and target disease with higher resolution and sensitivity could promote the detection of cancer and cardiac disease at much earlier stages. These agents could also be used to more rapidly and accurately monitor the effectiveness of treatments.
The National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory will apply its leading-edge nanotechnology characterization tools to evaluate the safety and feasibility of GE’s nanoparticle diagnostic imaging agents.
The cooperative research and development agreement between GE and NCI is the first under NCI’s new Advanced Technology Partnerships Initiative, which seeks to accelerate the delivery of new products to cancer patients.